Compare IDEXX Laboratories, Inc. (IDXX) vs JPMorgan Chase & Co (JPM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs JPMorgan Chase & Co — how do they compare? IDEXX Laboratories, Inc. trades at $519.93 (market cap $40.43B), while JPMorgan Chase & Co trades at $332.97 (market cap $880.98B). The key difference: JPMorgan Chase & Co is far larger — about 21.8× IDEXX Laboratories, Inc.'s market cap, and JPMorgan Chase & Co pays a 1.99% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and JPMorgan Chase & Co for 127 Days on average.
| IDXX | JPM | |
|---|---|---|
Market Cap | $40.43B | $880.98B |
Volume | 692,164 | 7,721,661 |
Sector | Health | Financials |
52-Week High | $766.68 | $365.18 |
52-Week Low | $504.70 | $282.84 |
Typical Hold Time | 46 Days | 127 Days |
Enterprise Value | $41.32B | $1.82T |
Dividend Yield | — | 1.99% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $517.47, up 2.13% with strong earnings momentum after beating Q2 2026 estimates. The stock shows bearish technical signals but maintains robust fundamentals with 25.03% net margins and 74.21% ROE. Recent acquisitions like CoVetAI and expanded diagnostic platforms highlight growth initiatives, while analyst consensus remains bullish with a $665 price target representing 28.5% upside potential.
The outlook remains positive given consistent earnings beats and expanding veterinary diagnostics market share. Key risks include FX headwinds, weaker U.S. vet visits, and premium valuations at 36x P/E. Institutional ownership trends show mixed activity with recent insider selling, but long-term growth drivers in pet healthcare innovation support the bullish analyst stance.
JPMorgan Chase & Co. (JPM) trades at $332.39, up 0.85% daily, with a bearish technical signal but strong fundamentals. Recent earnings show two beats out of three reported quarters, with Q3 2026 results pending. Revenue grew to $181.85B in 2025, though net income dipped to $57.05B. The stock is supported by a high ROE of 18.43% and a moderate P/E of 14.2, while analyst consensus is a 'Moderate Buy' with a $373.18 price target.
Outlook remains positive due to solid profitability and institutional support, but risks include geopolitical tensions, cybersecurity threats highlighted in recent news, and volatile cash flows. The stock offers value relative to peers, with upside potential if earnings momentum continues, though investors should monitor macroeconomic headwinds and upcoming Q3 earnings for direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About JPMorgan Chase & Co
JPMorgan Chase & Co. provides global financial services and retail banking. The Company provides services such as investment banking, treasury and securities services, asset management, private banking, card member services, commercial banking, and home finance. JP Morgan Chase serves business enterprises, institutions, and individuals.
Read more on JPM →
